Insider Selling: Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Insider Sells 10,000 Shares of Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Free Report) insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Friday, May 10th. The shares were sold at an average price of $16.37, for a total transaction of $163,700.00. Following the transaction, the insider now owns 1,164,662 shares of the company’s stock, valued at approximately $19,065,516.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN stock opened at $16.62 on Wednesday. The stock has a 50 day moving average price of $15.40 and a 200 day moving average price of $14.39. Day One Biopharmaceuticals, Inc. has a 52-week low of $9.67 and a 52-week high of $18.07. The firm has a market capitalization of $1.45 billion, a P/E ratio of -6.62 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Free Report) last released its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, sell-side analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.8 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DAWN. The Goldman Sachs Group decreased their target price on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Wedbush restated an “outperform” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research report on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, May 7th. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

View Our Latest Research Report on DAWN

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its position in Day One Biopharmaceuticals by 8.8% in the 3rd quarter. Arizona State Retirement System now owns 12,363 shares of the company’s stock valued at $152,000 after buying an additional 995 shares during the period. Quintet Private Bank Europe S.A. raised its stake in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after acquiring an additional 1,000 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 130.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after purchasing an additional 1,262 shares during the period. Hennion & Walsh Asset Management Inc. grew its stake in Day One Biopharmaceuticals by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock worth $979,000 after purchasing an additional 1,445 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in Day One Biopharmaceuticals by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 17,379 shares of the company’s stock worth $287,000 after purchasing an additional 1,447 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

(Get Free Report)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

Further Reading

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.